New Comprehensive Blood Safety Portfolio Launched at Arab Health 2014
By LabMedica International staff writers Posted on 04 Feb 2014 |
Image: Roche’s Cobas modular analyzer for the "Roche Blood Safety Solution" launched at Arab Health 2014 (Photo courtesy of Roche Diagnostics).
Image: Arab Health delegates meet with Roche delegates at the 2014 Arab Health Exhibition and Congress (Photo courtesy of Roche Diagnostics).
A first in the Middle East, a comprehensive blood-screening portfolio from a single source provides advanced serology screening and nucleic acid testing (NAT) technologies at blood centers, enhancing health standards in the region.
Roche Diagnostics Middle East (RDME), of the Roche company (Basel, Switzerland), has now launched the "Roche Blood Safety Solution" (RBSS) at the 2014 Arab Health Congress (Dubai, UAE), the largest healthcare exhibition and education congress in the Middle East. The RBSS portfolio, the first of its kind in the region, delivers reliability and workflow efficiency for Middle East blood centers, reaffirming RDME’s dedication to providing first class diagnostics in the region.
RBSS now enables patients and communities in the region to benefit from a dedicated, safe and efficient, reliable blood supply. The blood supply is made safe by a reduction in manual steps as well as excellent state-of-the-art assay sensitivity and genotype coverage. With technologies such as electrochemiluminescence (ECL) and polymerase chain reaction (PCR), laboratories benefit from high specificity and NAT real-time-target-discrimination. The systems provide the highest reliability available, excellent traceability and cross-contamination control, and less downtime.
Roche is the first IVD company to have a management center and a logistics hub in the Middle East, enabling RDME to develop from being a regional supplier into becoming a local IVD partner for its customers. The RBSS portfolio safeguards patients through leading technologies with dedication to, and investment in, the safety of the world’s blood supply. “Owing largely to our dedication to safeguard the world’s blood supply through technological innovations and drug development, Roche Diagnostics has become the preferred partner in the Blood Bank Industry,” said Michael Heuer, President of Europe, Middle East, Africa, and Latin America at Roche Diagnostics.
“RBSS benefits from the design, support, and streamlined supply chain that you would associate with [Roche]. We are proud to bring RBSS to the Middle East,” added Moritz Hartmann, General Manager of Roche Diagnostics Middle East. Roche offers service and support for reliability in all its workflow solutions, including the RBSS blood-screening platform, with dependable systems that help blood centers enhance workflow efficiency, minimizing processing time. The RBSS workflow solution is driving the concept of automation and setting new industry standards in diagnostic testing. Molecular testing processes will be brought together in a highly automated solution, without the need for manual transfer steps and with results calculated automatically and sent to the laboratory information system. The ease of operation coupled with ease of training result in staff competent in the use of RBSS systems. Furthermore, support structures in the Middle East help ensure operation of the systems with less downtime.
Related Links:
Roche
Arab Health Congress
Roche Diagnostics Middle East (RDME), of the Roche company (Basel, Switzerland), has now launched the "Roche Blood Safety Solution" (RBSS) at the 2014 Arab Health Congress (Dubai, UAE), the largest healthcare exhibition and education congress in the Middle East. The RBSS portfolio, the first of its kind in the region, delivers reliability and workflow efficiency for Middle East blood centers, reaffirming RDME’s dedication to providing first class diagnostics in the region.
RBSS now enables patients and communities in the region to benefit from a dedicated, safe and efficient, reliable blood supply. The blood supply is made safe by a reduction in manual steps as well as excellent state-of-the-art assay sensitivity and genotype coverage. With technologies such as electrochemiluminescence (ECL) and polymerase chain reaction (PCR), laboratories benefit from high specificity and NAT real-time-target-discrimination. The systems provide the highest reliability available, excellent traceability and cross-contamination control, and less downtime.
Roche is the first IVD company to have a management center and a logistics hub in the Middle East, enabling RDME to develop from being a regional supplier into becoming a local IVD partner for its customers. The RBSS portfolio safeguards patients through leading technologies with dedication to, and investment in, the safety of the world’s blood supply. “Owing largely to our dedication to safeguard the world’s blood supply through technological innovations and drug development, Roche Diagnostics has become the preferred partner in the Blood Bank Industry,” said Michael Heuer, President of Europe, Middle East, Africa, and Latin America at Roche Diagnostics.
“RBSS benefits from the design, support, and streamlined supply chain that you would associate with [Roche]. We are proud to bring RBSS to the Middle East,” added Moritz Hartmann, General Manager of Roche Diagnostics Middle East. Roche offers service and support for reliability in all its workflow solutions, including the RBSS blood-screening platform, with dependable systems that help blood centers enhance workflow efficiency, minimizing processing time. The RBSS workflow solution is driving the concept of automation and setting new industry standards in diagnostic testing. Molecular testing processes will be brought together in a highly automated solution, without the need for manual transfer steps and with results calculated automatically and sent to the laboratory information system. The ease of operation coupled with ease of training result in staff competent in the use of RBSS systems. Furthermore, support structures in the Middle East help ensure operation of the systems with less downtime.
Related Links:
Roche
Arab Health Congress
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data